coenzyme q10 and resveratrol protect against paclitaxel-induced nephrotoxicity in rats

Renal dysfunction caused by anticancer drugs may involve oxidants production. antioxidants have shown potential therapeutic effects on some disease conditions. this study examined the protective abilities of coenzyme q10 (coq10) and resveratrol (rsv) against paclitaxel (pcl)-induced renal dysfunction in rats. adult male albino rats (n=45) (210-230 g) were divided into 9 groups of n=5. groups c-e orally received coq10 (20 mg/kg), rsv (20 mg/kg) and coq10+ rsv daily for 5 days, respectively. group f received pcl (20 mg/kg) intraperitoneally (ip) on day 5. groups g-i were orally supplemented with coq10, rsv and coq10+ rsv daily for 5 days before a dose of pcl (20 mg/kg) on day 5. group a (placebo control) and group b (solvent control) received normal saline (0.2 ml) and corn oil (0.2 ml) daily for 5 days, respectively. the rats were anesthetized; blood samples were collected and assessed for serum biochemical markers. kidneys were assessed for melondialdehyde, antioxidants (superoxide dismutase, glutathione, glutathione peroxidase and catalase) and histology. body and kidney weights were normal (p>0.05) in pcl administered rats when compared to placebo control. serum electrolytes, total protein, albumin and kidney antioxidant levels were significantly (p<0.001) decreased whereas, serum creatinine, urea, uric acid and kidney malondialdehyde levels were significantly (p<0.001) increased in pcl administered rats when compared to control. hypercellular glomerulus and tubular necrosis were observed in the kidneys of pcl administered rats. pcl-induced renal dysfunction was significantly reversed by coq10 (p<0.05), rsv (p<0.01) and coq10+rsv (p<0.001) supplementations when compared to pcl. coq10 and rsv may clinically protect against pcl associated renal dysfunction